Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, contrasting to others tumors, such as breast cancer where miR-21 seems to be consistently upregulated; PCa data are controversial.
|
31416574 |
2020 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels.
|
30518628 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Over expressed MiR-21 in prostate cancer is associated with metastasis and drug resistance to chemotherapy with Docetaxel.
|
29447469 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These four most consistently reported dysregulated miRNAs viz. miRNA-141, miRNA-375, miRNA-221 and miRNA-21 need to be further validated in terms of their regulatory potential in regulating various pathways important for prostate cancer management.
|
29951892 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured levels of miR-21/146a/155 expression by quantitative real-time PCR (qRT-PCR), comparative ΔΔCt method, in fifteen patients with localized prostate cancer, treated with three-dimensional conformal radiotherapy (3DCRT).
|
30554863 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results of analysis of miR-21, miR-141, miR-18a and miR-221 in the plasma of PC patients showed that miR-18a is a powerful discriminator of PC patients from healthy controls as it had the highest AUC (0.966; 95% CI, 0.937-1.000), while miR-221 provided better differentiation of metastatic from localised PC (sensitivity was 92.9% at 100% specificity), and when we combine miR-18a and miR-221 for differentiating patients with MPC, it will increase the sensitivity to 96.4% at a specificity of 100% (AUC, 0.997; 95% CI, 0.988-1.0) (p < .000).
|
31483058 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies were included if they were designed to evaluate the diagnostic performance of miR-21 or miR-30c for PCa.
|
30881128 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relative expression of four miRNAs (miRNA-21, -93, -125b, and miRNA-221) was assessed in plasma from 149 newly diagnosed patients with local or locally advanced PCa.
|
30537232 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-21 promoted androgen-dependent and -independent PCa cell proliferation, migration, invasion, and resistance to apoptosis.
|
31002531 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-1 and miR-143 are frequently reduced in human prostate cancer (PCa), while miR-141 and miR-21 are frequently elevated.
|
29739972 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
α-Solanine, an active component of S. nigrum, is involved in the regulation of microRNA-21 (miRNA-21) (oncogenic) and miRNA-138 (tumor suppressor) in prostate cancer.
|
30076759 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
|
30014459 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of 29 health samples, 18 prostate cancer samples, 23 breast cancer samples imply that miR-141 and miR-21 are up-regulated in the prostate cancer samples and the breast cancer samples, respectively, and as reference miR-16 shows no difference in health and patient samples.
|
30428976 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promising preliminary results were published concerning miR-141, miR-375 and miR-21, but larger and prospective studies using standardized methodology are necessary to define the value of miRNAs in the detection and prognosis of PCa.
|
26751899 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
miR-21 can target and inhibit tumor suppressor gene PTEN expression to promote prostate cancer cell proliferation and invasion.
|
28107872 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding urinary exosomes, miR-21 and miR-375 were also significantly upregulated in PCa but no differences were found for miR-141.
|
27990656 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Four miRNAs (miRNA-21, miRNA-34a, miRNA-125, and miRNA-126) were significantly upregulated in PCa compared to benign prostatic hyperplasia (BPH), and except for miRNA-21 these miRNAs documented a positive correlation between the expression level in PCa cores and their matched BPH cores, (r > 0.72).
|
28628624 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that loss of miR-15 and miR-16 in cooperation with increased miR-21 expression promote prostate cancer spreading and bone lesions.
|
26073083 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Compared with adjacent non-cancerous prostate tissues, the expression level of miR-21 was significantly increased in PCa tissues (PCa vs. non-cancerous prostate: 1.3273 ± 0.3207 vs. 0.9970 ± 0.2054, P < 0.001).
|
27040772 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of miR-21 in PCa group were increased compared to BPH and control group (P < 0.05).
|
27434290 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, inhibition of miR-21-5p or miR-21-3p resulted in a significant decrease in ovarian and prostate cancer cell proliferation and invasion.
|
27166999 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluated the role of IL-6 in PDCD4 gene expression and how the microRNA miR-21 regulates this process in prostate cancer cell lines PC-3 and LNCaP.
|
26252635 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic (ROC) curve analysis revealed that the cut-off point of miR-21 for diagnosis of PCa was 0.9 with a sensitivity of 87.5% and a specificity of 85.7%.
|
26247873 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides statistical evidence that MMR deficiency is correlated with hypermethylation of hMLH1 promoter and upregulation of hsa-miR-155, hsa-miR-141 and hsa-miR-21 in prostate cancer.
|
25938433 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The performance of miRNAs 21 and 221 in differentiating prostate cancer from nonmalignant cases was evaluated and compared to DRE and elevated PSA. miRNA 21 was overexpressed in 90 % of group A vs. 10 % of group B, while miRNA 221 was overexpressed in 80 % of group A vs. 20 % of group B (p = 0.001).
|
25190021 |
2014 |